JPH01238526A - Vitamin e absorption-improving preparation - Google Patents
Vitamin e absorption-improving preparationInfo
- Publication number
- JPH01238526A JPH01238526A JP63062904A JP6290488A JPH01238526A JP H01238526 A JPH01238526 A JP H01238526A JP 63062904 A JP63062904 A JP 63062904A JP 6290488 A JP6290488 A JP 6290488A JP H01238526 A JPH01238526 A JP H01238526A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- absorption
- polyoxyethylene sorbitan
- preparation
- sorbitan monostearate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 229930003231 vitamin Natural products 0.000 title abstract 3
- 229940088594 vitamin Drugs 0.000 title abstract 3
- 235000013343 vitamin Nutrition 0.000 title abstract 3
- 239000011782 vitamin Substances 0.000 title abstract 3
- 150000003722 vitamin derivatives Chemical class 0.000 title abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 18
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940046009 vitamin E Drugs 0.000 claims abstract description 18
- 239000011709 vitamin E Substances 0.000 claims abstract description 18
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 18
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims abstract description 9
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims abstract description 9
- 238000010521 absorption reaction Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 17
- -1 sorbitan compounds Chemical compound 0.000 abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 7
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 5
- 239000000194 fatty acid Substances 0.000 abstract description 5
- 229930195729 fatty acid Natural products 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 235000011187 glycerol Nutrition 0.000 abstract description 3
- 239000003921 oil Substances 0.000 abstract description 3
- 235000019198 oils Nutrition 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract description 2
- 150000001298 alcohols Chemical class 0.000 abstract description 2
- 235000019441 ethanol Nutrition 0.000 abstract description 2
- 150000004665 fatty acids Chemical class 0.000 abstract description 2
- 239000004094 surface-active agent Substances 0.000 abstract description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract description 2
- 239000008158 vegetable oil Substances 0.000 abstract description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 239000003925 fat Substances 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000007902 hard capsule Substances 0.000 description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 6
- 229940042585 tocopherol acetate Drugs 0.000 description 6
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Abstract
Description
【発明の詳細な説明】 ［産業上の利用分野］ 本発明はビタミンＥの経口吸収改善製剤に関する。[Detailed description of the invention] [Industrial application field] The present invention relates to a preparation for improving oral absorption of vitamin E.
［従来の技術］
ビタミンＥは、血液循環障害、毛細血管内の血流停滞を
改善するだけでなく、感染症や癌、更には虚血性心疾患
の出現率を減少させるのに重要な働き゛をしていると言
われている。[Prior Art] Vitamin E not only improves blood circulation disorders and stagnation of blood flow in capillaries, but also plays an important role in reducing the incidence of infectious diseases, cancer, and even ischemic heart disease. It is said that he is doing
しかしながら、毎日摂取される食事の内容を変更するこ
とによって血漿中のビタミンＥ濃度を上昇させることは
容易ではない。However, it is not easy to increase the vitamin E concentration in plasma by changing the contents of daily meals.
その上、−膜内にビタミンＥの消化管からの吸収には限
界があると認められるために臨床用量での吸収性に問題
があるとされている。例えば小動物（ラット）での吸収
率はわずかに１０〜４２％と見積もられるし、マックリ
ンが最近報告したヒトの結果［インファケム、第７巻、
第３号、第２４ページ（１９８６年）コでもｄｌ−酢酸
トフフェロール８００１、Ｕ、２８日間連日経口投与し
た時、血漿中濃度が之倍程度となるに過ぎない。Furthermore, it is recognized that there is a limit to the absorption of vitamin E from the gastrointestinal tract within the membrane, which poses a problem in absorption at clinical doses. For example, the absorption rate in small animals (rats) is estimated to be only 10-42%, and Macklin recently reported human results [Infachem, Vol. 7,
No. 3, page 24 (1986), when dl-topherol acetate 8001, U, was orally administered for 28 consecutive days, the plasma concentration was only about twice that.
この為、ビタミンＥの消化管吸収を改善するために種々
の試みがなされてきた。その１つとして、ポリオキシエ
チレンソルビクンモノオレートなどのポリオキシエチレ
ンソルビタン詣肪酸エステル類添加による可溶化効果を
期待する方法がある。すなわち、ケラ−（Ｋａｌｌ−ｅ
ｒ ）らはラットに落花生油あるいはポリ才キシエチレ
ンソルビクンモノオレートの投与形態で６０〜７６％の
吸収率を報告している〔インターナショナル・ジャーナ
ル・才ブ・ビタミノロジー・アンド・二二一トリッショ
ナル・リサーチ、第４２巻、第３９４ページ（１９７２
年〕］。また、ベイトマン（Ｂａｔｅｍａｎ ）らはポ
リオキシエチレンソルビタンモノオレート、エタノール
及びプロピレングリコールより成る基剤を使って、ｄ−
α−トフフエロールをヒトに投与したところ、市販の錠
剤や油製剤よりも吸収が向上する゛ことを報告している
。For this reason, various attempts have been made to improve the gastrointestinal absorption of vitamin E. One such method is to expect a solubilizing effect by adding polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbicun monooleate. That is, Kall-e
reported an absorption rate of 60% to 76% in rats using peanut oil or polyoxyethylene sorbicun monooleate [International Journal of Vitaminology and 221 Tri. National Research, Volume 42, Page 394 (1972
Year〕]. Also, Bateman et al. used a base consisting of polyoxyethylene sorbitan monooleate, ethanol, and propylene glycol to
When α-tofuferol was administered to humans, it was reported that absorption was improved compared to commercially available tablets and oil preparations.
［発明が解決しようとする課題］
一般に、ポリオキシエチレンソルビタン脂肪酸エステル
類などの非イオン性界面活性剤の添加はビタミンＥの消
化管吸収をある程度改善するが、高投与量での吸収の不
完全性などを考慮に入れると、更番こ吸収の優れた製剤
の開発が望まれている。[Problem to be solved by the invention] Generally, the addition of nonionic surfactants such as polyoxyethylene sorbitan fatty acid esters improves the gastrointestinal absorption of vitamin E to some extent, but absorption is incomplete at high doses. Taking into consideration the characteristics, it is desired to develop a formulation with excellent absorption of serobanco.
〔課題を解決するだめの手段］
このような実情に鑑み、本発明者らはビタミンＥの消化
管からの吸収性に対する基剤の効果を種々検討した結果
、意外にもポリオキシエチレンソルビタンモノステアレ
ートがポリオキシエチレンソルビタンモノオレートや他
のポリオキシエチレンソルビタン脂肪酸エステル類を配
合した時よりも、消化管からのビタミンＥの吸収が増大
することを見い出し、本発明を完成するに至った。[Means to Solve the Problem] In view of the above circumstances, the present inventors investigated various effects of bases on the absorption of vitamin E from the gastrointestinal tract, and found that polyoxyethylene sorbitan monostearer The present inventors have discovered that absorption of vitamin E from the digestive tract is increased compared to when polyoxyethylene sorbitan monooleate or other polyoxyethylene sorbitan fatty acid esters are blended, leading to the completion of the present invention.
すなわち、本発明は１重量部のビタミンＥに対し０．０
１〜１０重量部のポリオキシエチレンソルビタンモノス
テアレートを配合することを特徴とするビタミンＥの経
口吸収改善製剤である。That is, the present invention provides 0.0 parts by weight of vitamin E.
This is a preparation for improving the oral absorption of vitamin E, which is characterized by containing 1 to 10 parts by weight of polyoxyethylene sorbitan monostearate.
本発明は、ビタミンＥを含有する経口製剤に適した剤層
中に特定量のポリオキシエチレンソルビタンモノステア
レートを配合することによって実施することができる。The present invention can be carried out by incorporating a specific amount of polyoxyethylene sorbitan monostearate into a drug layer suitable for oral formulations containing vitamin E.
この１重量部のビタミンＥに対してのポリオキシエチレ
ンソルビタンモノステアレートの配合量は、０．０１〜
１０重量部であり、好ましくは１重量部〜１０重量部の
ポリオキシエチレンソルビタンモノまた、本発明におい
て、ビタミンＥとは、トフフェロール、酢酸トコフェロ
ール、フハク酸トコフェロール、フハク酸トフフエロー
ルカルシウム及びその他のエステル類を言う。The blending amount of polyoxyethylene sorbitan monostearate for 1 part by weight of vitamin E is 0.01 to
10 parts by weight, preferably 1 to 10 parts by weight of polyoxyethylene sorbitan mono. Also, in the present invention, vitamin E refers to tofuferol, tocopherol acetate, tocopherol succinate, tofuferol calcium succinate and other Refers to esters.
また、上記製剤には脂肪酸及び植物油などの油詣類する
いはプロピレングリコール、エタノール又はグリセリン
などのアルコール類、ソルビタン類などの界面活性剤、
その他の製剤添加物を第３成分として添加しても良い。In addition, the above formulations may contain oils such as fatty acids and vegetable oils, alcohols such as propylene glycol, ethanol or glycerin, and surfactants such as sorbitans.
Other formulation additives may be added as a third component.
この場合、配合割合は特に限定しないが通常、製剤に対
し０．５〜５０重量％であることが望ましい。In this case, the blending ratio is not particularly limited, but it is usually desirable to be 0.5 to 50% by weight based on the formulation.
［発明の効果］
本発明により、ビタミンＥの可溶性能及び消化管からの
吸収性が高まり、バイオアベイラビリティ−が向上した
。[Effects of the Invention] According to the present invention, the solubility and absorbability of vitamin E from the gastrointestinal tract were increased, and the bioavailability was improved.
［、実１例コ
以下、実施例および試験例を挙げて本発明を具体的に説
明する。[Example 1] Hereinafter, the present invention will be specifically explained with reference to Examples and Test Examples.
東ＪＬ例」２
酢酸トコフェロール１ｇをポリオキシエチレンソルビタ
ンモノステアレート２ｇと共に加温溶解し、２号の硬カ
プセル１５個に充填した。East JL Example 2 1 g of tocopherol acetate was dissolved by heating with 2 g of polyoxyethylene sorbitan monostearate, and the mixture was filled into 15 No. 2 hard capsules.
夫１■ユ
酢酸トコフェロール１ｇをポリオキシエチレンソルビタ
ンモノステアレート２ｇと共に加温溶解後、大豆油１ｇ
を加え、攪拌後常法により、２号の硬カプセル１５個に
充填した。Husband 1: Dissolve 1g of tocopherol euacetate with 2g of polyoxyethylene sorbitan monostearate by heating, then add 1g of soybean oil.
was added, stirred, and then filled into 15 No. 2 hard capsules by a conventional method.
夫五勇ユ
α−トコフェロール１ｇをポリオキシエチレンソルビタ
ンモノステアレート２ｇと加温混和後、グリセリン０．
５ｇ及びプロピレングリコール０．５ｇをｐえ、攪拌後
、常法により、３１号の硬カプセル１５個に充填した。After heating and mixing 1 g of Fugoyu α-tocopherol with 2 g of polyoxyethylene sorbitan monostearate, 0.0 g of glycerin was added.
5 g and propylene glycol 0.5 g, stirred, and filled into 15 No. 31 hard capsules by a conventional method.
実ＪＥ医〕ヨ
フハク酸トフフェロール１０ｇをボリ才キシエチレンツ
ルビクンモノステアレート１０ｇと共に加温溶解し、こ
の溶液をヒドロキシプロピルセルロース２５ｇ、結晶セ
ルロース３０ｇ及び乳糖３０ｇの混合物に均一に分散さ
せた。Practical JE Doctor] 10 g of topherol iosuccinate was dissolved by heating together with 10 g of polyoxyethylene turvikun monostearate, and this solution was uniformly dispersed in a mixture of 25 g of hydroxypropyl cellulose, 30 g of crystalline cellulose, and 30 g of lactose.
次いで、この分散物を乾燥整粒後、ステアリン酸マグネ
シウム１ｇを加えて混合し、１錠１００ｍｇの錠剤１０
００個を圧縮成形した。Next, after drying and sizing this dispersion, 1 g of magnesium stearate was added and mixed to form 100 mg tablets.
00 pieces were compression molded.
実施例５
酢酸トコフェロール１ｇをポリオキシエチレンソルビク
ンモノステアレート０．５ｇと加温溶解後、パナセート
８１０２．５ｇを加え、攪拌後、常法により２号の軟カ
プセル１５個に充填した。Example 5 After heating and dissolving 1 g of tocopherol acetate with 0.5 g of polyoxyethylene sorbicun monostearate, 8102.5 g of panasate was added, and after stirring, the mixture was filled into 15 No. 2 soft capsules by a conventional method.
試験例１（バイオアベイラビリティ−試験）（検体）
検体１；実施例１の硬カプセル剤
検体２；酢酸トコフェノール１００ｎｔとポリオキシエ
チレンソルビタンモノオレート２００■を１カプセル中
に含む硬カプセル剤
検体３；酢酸トコフェロールの原体のみ１００■を含有
する硬カプセル剤
検体４；酢酸トコフェロール１００ＴｒＶ、とポリオキ
シエチレンソルビタンモノオレート１６０■、プロピレ
ングリフール２０■及びエタノール２０■を含有する硬
カプセル剤
（試験動物）
試験実施前日より絶食きせたピーグル大（体重１０〜１
３ｋｇ）を１群３頭用いた。Test Example 1 (Bioavailability Test) (Sample) Sample 1; Hard capsule sample 2 of Example 1; Hard capsule sample 3 containing 100 nt of tocopherol acetate and 200 ml of polyoxyethylene sorbitan monooleate in one capsule; Hard capsule containing 100 µV of tocopherol acetate only; Hard capsule containing 100 TrV of tocopherol acetate, 160 µ of polyoxyethylene sorbitan monooleate, 20 µ of propylene glyfur, and 20 µ of ethanol (test animal) Peagle-sized (weight 10-1
3 kg) were used in each group.
（投与方法）
各検体をそれぞれ別個の群のピーグル犬に経口投与し、
直後に水３０ｍ１を強制的に投与した。(Administration method) Each sample was orally administered to a separate group of peagle dogs,
Immediately thereafter, 30 ml of water was forcibly administered.
（血液試料の採取と処理）
゛投与直前、投与後２時間、４時間、６時間、８時間及
び２４時間目に前足静脈血液３ｍＱを採取して遠心分離
後の血漿を試料とした。(Collection and processing of blood samples) Immediately before administration, 2 hours, 4 hours, 6 hours, 8 hours, and 24 hours after administration, 3 mQ of foreleg vein blood was collected, and the plasma after centrifugation was used as a sample.
（定量法）
各血漿中の総α−トコフェロール濃度は高速クロマトグ
ラフィーにより測定した。(Quantitative method) The total α-tocopherol concentration in each plasma was measured by high performance chromatography.
すなわち、試料０．５ｍｌに蒸留水０．５ｍｌを加え希
釈し、エタノール０゜５ｍｌで除タンパクした後にヘキ
サン５ｍｌを加え抽出した。１０分間振盪し、遠心分離
した後ヘキサン層４ｍｌを採取した。That is, 0.5 ml of a sample was diluted by adding 0.5 ml of distilled water, protein was removed with 0.5 ml of ethanol, and then 5 ml of hexane was added for extraction. After shaking for 10 minutes and centrifuging, 4 ml of hexane layer was collected.
ヘキサン層を蒸発乾固し残渣にエタノールを加え、これ
を高速液体クロマトグラフに注入した。The hexane layer was evaporated to dryness, ethanol was added to the residue, and this was injected into a high performance liquid chromatograph.
カラムは長さ１５（ｌｌｎ、直径４ｍｍのものを用い、
充填剤としてＴＳＫ−Ｇｅｌ ＬＳ−４１０（東洋曹達
）を用いた。溶離液はメタノール：水の混液（９４：６
）を用い、検出は２９１ｎｍの紫外部吸収波長を使用し
た。The column used was one with a length of 15 (lln) and a diameter of 4 mm.
TSK-Gel LS-410 (Toyo Soda) was used as a filler. The eluent was a mixture of methanol and water (94:6).
), and the ultraviolet absorption wavelength of 291 nm was used for detection.
（結果）
投与直前の血漿濃度を差し引いた各採血時点の第１表
本発明により得られた検体１は対照として用いた検体２
，３．４よりも高い血中濃度を示した。(Results) Table 1 for each blood collection time point after subtracting the plasma concentration immediately before administration Sample 1 obtained according to the present invention is Sample 2 used as a control
, 3.4.
Claims (1)
重量部のポリオキシエチレンソルビタンモノステアレー
トを配合することを特徴とするビタミンＥの経口吸収改
善製剤。1) 0.01 parts by weight to 10 parts by weight per 1 part by weight of vitamin E
A preparation for improving oral absorption of vitamin E, which contains part by weight of polyoxyethylene sorbitan monostearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63062904A JP2676770B2 (en) | 1988-03-16 | 1988-03-16 | Vitamin E absorption improving preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63062904A JP2676770B2 (en) | 1988-03-16 | 1988-03-16 | Vitamin E absorption improving preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01238526A true JPH01238526A (en) | 1989-09-22 |
| JP2676770B2 JP2676770B2 (en) | 1997-11-17 |
Family
ID=13213706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63062904A Expired - Fee Related JP2676770B2 (en) | 1988-03-16 | 1988-03-16 | Vitamin E absorption improving preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2676770B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0532547A (en) * | 1991-07-26 | 1993-02-09 | Ss Pharmaceut Co Ltd | Vitamin e pharmaceutical composition |
| JP2002020268A (en) * | 2000-07-10 | 2002-01-23 | Takeda Chem Ind Ltd | Internal liquid containing fat-soluble substance |
| FR2861261A1 (en) * | 2003-10-22 | 2005-04-29 | Adisseo France Sas | The use in animal nutrition of alimentary emulsifiers, especially sorbitol monolaurate and monooleate in association with a derivative of vitamin E, especially tocopherol acetate to improve its bioavailability |
| EP1696902A4 (en) * | 2003-12-23 | 2007-03-07 | Cognis Ip Man Gmbh | Compositions containing d-tocopherol compound polybasic acid partial esters |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6034907A (en) * | 1983-05-02 | 1985-02-22 | アール・ピー・シエラー・コーポレイシヨン | Vitamin or mineral composition for forming solid unit administration form |
-
1988
- 1988-03-16 JP JP63062904A patent/JP2676770B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6034907A (en) * | 1983-05-02 | 1985-02-22 | アール・ピー・シエラー・コーポレイシヨン | Vitamin or mineral composition for forming solid unit administration form |
| JPS60105633A (en) * | 1983-05-02 | 1985-06-11 | ア−ル・ピ−・シエアラ−・プロプライアタリ−・リミテツド | Vitamin composition |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0532547A (en) * | 1991-07-26 | 1993-02-09 | Ss Pharmaceut Co Ltd | Vitamin e pharmaceutical composition |
| JP2002020268A (en) * | 2000-07-10 | 2002-01-23 | Takeda Chem Ind Ltd | Internal liquid containing fat-soluble substance |
| FR2861261A1 (en) * | 2003-10-22 | 2005-04-29 | Adisseo France Sas | The use in animal nutrition of alimentary emulsifiers, especially sorbitol monolaurate and monooleate in association with a derivative of vitamin E, especially tocopherol acetate to improve its bioavailability |
| EP1696902A4 (en) * | 2003-12-23 | 2007-03-07 | Cognis Ip Man Gmbh | Compositions containing d-tocopherol compound polybasic acid partial esters |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2676770B2 (en) | 1997-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0326618A1 (en) | Medicinal composition containing albumin as carrier and process for its preparation | |
| RU2462250C2 (en) | New composition of cholest-4-en-3-one oxime | |
| EP0023349B1 (en) | Ubidecarenone composition enhancing the absorption | |
| JP4086501B2 (en) | Oral microemulsion composition containing silybin | |
| EP0818196B1 (en) | Capsule, containing dioxabicyclo(3.3.0)octane compounds | |
| JPH0276819A (en) | Fatty acid composition | |
| JP3285410B2 (en) | Oral pharmaceutical composition containing anthocyanosides | |
| JPH11512115A (en) | Pharmaceutical composition for oral administration | |
| JP5844954B2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING EXTERIOR EXTRACT AND METHOD FOR PRODUCING THEM | |
| CN103830204A (en) | Soft capsule containing silybum marianum extract and preparation method of soft capsule | |
| JP2677613B2 (en) | Absorption promoting composition of vitamin E or derivative thereof | |
| JP3075358B2 (en) | Liver function improver | |
| WO2000053212A1 (en) | Pharmaceutical composition containing cyclosporin | |
| KR102096391B1 (en) | Omega-3-fatty acid composition forming liquid crystal structures | |
| JPH01238526A (en) | Vitamin e absorption-improving preparation | |
| JPS63188623A (en) | Ubidecarenone preparation having improved absorption | |
| JP4690334B2 (en) | Oral microemulsion composition comprising biphenyldimethyldicarboxylate and silybin | |
| CA2304493A1 (en) | Flavonolignan preparations, especially silymarin preparations | |
| JP2973077B2 (en) | Vitamin E preparation composition | |
| KR20040047056A (en) | Oral micro-emulsion composition comprising biphenyldimethyldicarboxylate | |
| JPS59148718A (en) | Ubidecarenone composition | |
| US4006252A (en) | Methods and compositions for reducing plasma lipid levels | |
| JPH01128921A (en) | Pharmaceutical for promoting absorption of vitamin a | |
| CN1615899B (en) | Puerarin oral preparation | |
| TWI292315B (en) | Composition for decreasing lipids in blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |